EU authorises AstraZeneca Covid-19 vaccine, 400 mn doses to be available

It was the third COVID-19 vaccine authorized in the EU, after Pfizer/BioNTech and Moderna vaccines were given the greenlights in late December and early January

Topics
Coronavirus | Coronavirus Vaccine | AstraZeneca

ANI  |  US 

Photo: Reuters
The authorization was granted hours after the European Medicines Agency (EMA) issued a positive scientific recommendation.

The European Commission on Friday granted a conditional marketing authorisation (CMA) for the COVID-19 vaccine developed by multinational pharmaceutical company

"Today, the European Commission has granted a conditional marketing authorisation (CMA) for the COVID-19 vaccine developed by AstraZeneca, the third COVID-19 vaccine authorised in the EU," the European Commission said in a statement.

The commission said that the vaccine will be given to adults aged 18 years and older for preventing COVID-19.

This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness, and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States, the commission said.

The President of the European Commission, Ursula von der Leyen, said: "Securing safe vaccines for Europeans is our utmost priority. With the vaccine now authorized, 400 million additional doses will be available in Europe. I expect the company to deliver these doses as agreed so that Europeans can be vaccinated as soon as possible. We will continue doing all we can to secure more vaccines for Europeans, our neighbors, and our partners worldwide."

Stella Kyriakides, Commissioner for Health and Food Safety, said: "The European Medicines Agency's authorisation today is another step towards delivering on this promise. The Commission continues to work around the clock to secure more vaccines for Europe and our international partners. We are leaving no stone unturned in our fight against this pandemic."

According to EMA, most of the participants in the studies were between 18 and 55 years old. There are not yet enough results in older participants (over 55 years old) to provide a figure for how well the vaccine will work in this group.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus
First Published: Sat, January 30 2021. 06:37 IST
RECOMMENDED FOR YOU